Ocular Therapeutix
Biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye.
Launch date
Employees
Market cap
€1.3b
Enterprise valuation
€927m (Public information from Sep 2024)
Share price
$9.05 OCUL
Bedford Texas (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 17.4m | 43.5m | 51.5m | 58.4m | 66.2m | 75.0m | 95.3m |
| % growth | 312 % | 150 % | 18 % | 13 % | 13 % | 13 % | 27 % |
| EBITDA | (62.7m) | (78.0m) | (77.9m) | (75.4m) | (146m) | 1.3b | (166m) |
| % EBITDA margin | (360 %) | (179 %) | (151 %) | (129 %) | (220 %) | 1791 % | (174 %) |
| Profit | (156m) | (6.6m) | (71.0m) | (80.7m) | (180m) | (162m) | (149m) |
| % profit margin | (894 %) | (15 %) | (138 %) | (138 %) | (272 %) | (216 %) | (157 %) |
| EV / revenue | 79.3x | 9.7x | 3.3x | 8.4x | 20.8x | 18.4x | 14.4x |
| EV / EBITDA | -22.0x | -5.4x | -2.2x | -6.5x | -9.4x | 1.0x | -8.3x |
| R&D budget | 28.7m | 50.1m | 53.5m | 61.1m | - | - | - |
| R&D % of revenue | 165 % | 115 % | 104 % | 104 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | $1.0m | Series A | |
| N/A | $6.0m | Series B | |
$15.0m | Series C | ||
$6.0m | Series C | ||
$14.0m | Series D | ||
$8.5m | Series E | ||
| N/A | N/A | IPO | |
* | N/A | $88.0m | Post IPO Equity |
| N/A | $35.1m | Post IPO Equity | |
| N/A | $37.5m | Post IPO Debt | |
* | N/A | $45.0m | Post IPO Equity |
* | N/A | $100m | Post IPO Equity |
* | $325m | Private Placement VC | |
| Total Funding | €341m | ||
Related Content
Recent News about Ocular Therapeutix
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.